Psychopharmacological treatment of anorexia nervosa and bulimia. Review and synthesis.
Recent reports have indicated that the incidence of anorexia nervosa and bulimia has increased over the last several years. Both of these syndromes present serious treatment challenges to clinicians and in an effort to deal more effectively with these disorders several pharmacological interventions have been attempted. This article reviews the range of pharmacological interventions used with anorexia nervosa and bulimia patients. The purpose of the review is to present our current knowledge regarding the efficacy of these medications and to offer methodological recommendations that will enhance future research efforts.
D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000856:Anorexia Nervosa / Q000188:drug therapy* / Q000503:physiopathology; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D002746:Chlorpromazine / Q000627:therapeutic use; D003533:Cyproheptadine / Q000627:therapeutic use; D004298:Dopamine / Q000502:physiology; D001068:Feeding and Eating Disorders / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006963:Hyperphagia / Q000188:drug therapy* / Q000503:physiopathology; D007980:Levodopa / Q000627:therapeutic use; D008094:Lithium / Q000627:therapeutic use; D016651:Lithium Carbonate; D008297:Male; D009270:Naloxone / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D010868:Pimozide / Q000627:therapeutic use; D012701:Serotonin / Q000502:physiology; D015032:Zinc / Q000627:therapeutic use
D000929:Antidepressive Agents, Tricyclic; D010868:Pimozide; D016651:Lithium Carbonate; D003533:Cyproheptadine; D012701:Serotonin; D009270:Naloxone; D007980:Levodopa; D010672:Phenytoin; D000324:Adrenocorticotropic Hormone; D008094:Lithium; D015032:Zinc; D002746:Chlorpromazine; D004298:Dopamine